ГЛЮКАГОНОПОДОБНЫЙ ПЕПТИД-1: ОТ ФИЗИОЛОГИИ К ЭФФЕКТИВНОМУ УПРАВЛЕНИЮ САХАРНЫМ ДИАБЕТОМ 2 ТИПА


Цитировать

Полный текст

Аннотация

Научные разработки последних лет позволили досконально изучить роль инкретиновых гормонов в регуляции метаболизма углеводов в организме человека и их влияние на β-клетку, а также создать новое направление фармакотерапии сахарного диабета 2 типа. Представлен анализ результатов нескольких прямых сравнительных исследований различных инкретиновых препаратов. По сравнению с другими доступными сегодня препаратами группы инкретинов лираглутид (Виктоза) имеет высокую клиническую эффективность и безопасность.

Об авторах

М Б Анциферов

Эндокринологический диспансер Департамента здравоохранения г. Москвы

Эндокринологический диспансер Департамента здравоохранения г. Москвы

M B Antsiferov

Список литературы

  1. Levy P. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease. Postgrad Med. 2009;121(3 Suppl. 1):7-12.
  2. Nathan DM, et al. American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a con-sensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
  3. Rodbard HW, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
  4. Maedler K, et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501-6.
  5. Takahashi A, et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res Clin Pract 2007;77:343-50.
  6. Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
  7. Riedel AA, et al. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am J Manag Care 2007;13:457-63.
  8. Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Am J Med 2009;122(6A, Suppl.):11-24.
  9. U.K. Prospective Diabetes Study Group: Overview of 6 years therapy of type 2 diabetes: a progressive disease. Diabetes 1995;44:1249-58.
  10. Butler AE, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10.
  11. Vilsbøll T, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002;45:1111-19.
  12. Knudsen LB, et al. Potent derivatives of glucagon-like peptide-1with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43(9):1664-69.
  13. Steensgaard DB, et al. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide [abstract]. Diabetes 2008;57(Suppl. 1):552.
  14. Farilla L, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143(11):4397-408.
  15. Buteau J, et al. Glucagon-like peptide-1 induces pancreatic betta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52(1):124-32.
  16. Elbrønd B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25:1398-404.
  17. Garber A. Incretin effects on beta-cell function, replication and mass: the human perspective. Diabetes Care 2011;34(Suppl. 2):258-63.
  18. Pratley RE, et al.; 1860-LIRA-DPP-4 Study Group: Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56.
  19. Davies M, et al. One-Year Liraglutide Treatment Reduces A1C to a Greater Extent than Sitagliptin, both in Combination with Metformin, Independent of Baseline A1C LevelsDiabetes 2011;60(Suppl. 1):Abstract 2314.
  20. Pratley RE, et al. Diabetes 2011;60(Suppl. 1):Abstract 1119.
  21. Pratley RE, et al. One-Year Liraglutide Treatment Offers Greater Weight Reduction and More Improved Glycemic Control Compared with Sitagliptin, Both in Combination with Metformin. Diabetes 2011;60(Suppl. 1):abstract 2313.
  22. Irie S, et al. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther 2008;46(6):273-79.
  23. Buse JB, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
  24. Buse JB, et al. Frequency and magnitude of antibody forma¬tion are lower with liraglutide than exenatide: LEAD-6 Results (Abstract 676). Presented at the 70th Scientific Sessions of the American Diabetes Association, Orlando, Fla., 2010.
  25. Bayley T, et al. Comparison of Incretin-Based Therapies: Liraglutide Offers Greater Improvements in A1C than Sitagliptin or Exenatide Across Baseline A1C Categories. Diabetes 2011;60(Suppl. 1):Abstract 2252.
  26. Amylin Pharmaceuticals: BYETTA package insert, 2008. Available online from http://pi.lilly.com/us/byetta-pi.pdf. Accessed 22 September 2010.
  27. U.S. Food and Drug Administration: Information for healthcare professionals: acute pancreatitis and sitagliptin (marketed as Januvia and Janumet), 2009. Available online from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm. Accessed 22 September 2010.
  28. Noel RA, et al. Increased risk of acut pancreatitis and biliary disease observed in patients with tipy 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32(5):834-38.
  29. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.
  30. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemia and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
  31. Nauck MA, Frid A, Hermansen K, et al.; for the LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009;32(1):84-90.
  32. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009;52:2046-55.
  33. Zinman B, Gerich J, Buse J, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32(7):1224-30.
  34. Bjerre Knudsen L, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-1486.
  35. Garber A. AACE Statement on Liraglutide (March 2010). Accessed June 24,2011.
  36. Jacobsen LV, et al. Pharmacokinetics of the long-acting human GLP-1 analog liraglutide in subjects with renal impairment. Diabetes 2007;56(Suppl 1):A137.
  37. Flint A, et al. Influence io hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analog liraglutide. Diabetes 2007;56(Suppl. 1):145.
  38. Дедов И.И., Шестакова М.В. и др. Алгоритмы специализированной медицинской помощи больным с сахарным диабетом (5-й выпуск) // Сахарный диабет. 2011. № 4. (Приложение). 72 с.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2012